Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument

Holvoet, Tom; Raevens, Sarah; Vandewynckel, Yves-Paul; Biesen, Wim Van; Geboes, Karen; Vlierberghe, Hans Van

doi:10.1016/j.dld.2015.07.005

Cited by 10 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Domain 1 (scope and purpose) and domain 4 (clarity of presentation) have obtained the highest scores, both of which with a score above 90%. This finding was consistent with the results of the previous studies on the appraisal of clinical guidelines using AGREE II tool, which covered various clinical topics (19,21,22,(30)(31)(32)(33). Such high scores are a result of full explanations of these domains presented by clinical guidelines developers.…”

Section: Discussionsupporting

confidence: 91%

The Critical Assessment of the Quality of Common Clinical Guidelines for Administering Chemotherapy Drugs by Using AGREE II Tool

2019

View full text Add to dashboard Cite

Context: Administering chemotherapy drugs in patients with cancer is a complicated and risky process that may have the potential to harm patients and the healthcare team if not done safely. Objectives: This study aimed to evaluate the quality of current clinical guidelines for the administration of chemotherapy drugs by using the appraisal of guidelines for research & evaluation II (AGREE II) tool. Evidence Acquisition: After searching through authoritative databases and publishing clinical guidelines by institutions, the articles which were published between 2007 to August 2018 with selected keywords were reviewed and the clinical guidelines were evaluated independently by 5 experts using AGREE II tool based on the inclusion and exclusion criteria. The consensus between appraisers was examined using the ICC (intraclass correlation coefficient). Results: Among 51 clinical guidelines, 4 of them were matched with the inclusion criteria. All 4 clinical guidelines had a high level of quality, with a minimum score above 60% in their 5 domains. Domain 1(scope and purpose) obtained the highest score (95.27 %) and domain 3 (rigor of development) obtained the lowest score (84.89%). The degree of agreement between evaluators was very good (0.84-0.95). Conclusions: The overall quality of current clinical guidelines for administering chemotherapy drugs which were evaluated by AGREE II tool, is satisfactory. Therefore, their clinical implementation is recommended to the entire health care team and nurses working in oncology departments, in order to improve the safety of patients and the health care team, and also to prevent the complications of chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 91%

The Critical Assessment of the Quality of Common Clinical Guidelines for Administering Chemotherapy Drugs by Using AGREE II Tool

2019

View full text Add to dashboard Cite

show abstract

“…The quest for optimal and reliable guidelines based on robust evidence for the treatment of cholangiocarcinoma and without appeal: "Overall, the methodological quality of guidelines on the surgical management of cholangiocarcinoma is poor." This type of conclusion of guidelines appraisal is common: the quality scores as measured with the AGREE Instrument have remained moderate to low over the last two decades in general (6) and specifically in the field of liver tumors (7)(8)(9). In brief, most often, "guidelines do not fulfill the guidelines to build them".…”

Section: Viewpointmentioning

confidence: 99%

The quest for optimal and reliable guidelines based on robust evidence for the treatment of cholangiocarcinoma

Azoulay¹,

Bomze²,

Meirson³

2021

Hepatobiliary Surg Nutr

View full text Add to dashboard Cite

“…Hepatocellular carcinoma (HCC) is the most common primary liver cancer. HCC is the sixth most prevalent cancer, and the second leading cause of cancer mortality[ 1 ]. The incidence of HCC in different countries is related mostly to the geographic prevalence of certain risk factors such as chronic hepatitis B and C, aflatoxins, and alcoholism[ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises)

El‐Nakeep¹

2022

WJGP

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second cause of cancer-related mortality. The diagnosis of HCC depends mainly on -fetoprotein, which is limited in its diagnostic and screening capabilities. There is an urgent need for a biomarker that detects early HCC to give the patients a chance for curative treatment. New targets of therapy could enhance survival and create future alternative curative methods. In silico analysis provides both; discovery of biomarkers, and understanding of the molecular pathways, to pave the way for treatment development. This review discusses the role of in silico analysis in the discovery of biomarkers, molecular pathways, and the role the author has contributed to this area of research. It also discusses future aspirations and current limitations. A literature review was conducted on the topic using various databases (PubMed, Science Direct, and Wiley Online Library), searching in various reviews, and editorials on the topic, with overviewing the author’s own published and unpublished work. This review discussed the steps of the validation process from in silico analysis to in vivo validation, to incorporation into clinical practice guidelines. In addition, reviewing the recent lines of research of bioinformatic studies related to HCC. In conclusion, the genetic, molecular and epigenetic markers discoveries are hot areas for HCC research. Bioinformatics will enhance our ability to accomplish this understanding in the near future. We face certain limitations that we need to overcome.

show abstract

Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument

Cited by 10 publications

References 33 publications

The Critical Assessment of the Quality of Common Clinical Guidelines for Administering Chemotherapy Drugs by Using AGREE II Tool

The Critical Assessment of the Quality of Common Clinical Guidelines for Administering Chemotherapy Drugs by Using AGREE II Tool

The quest for optimal and reliable guidelines based on robust evidence for the treatment of cholangiocarcinoma

Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises)

Contact Info

Product

Resources

About